Abstract：
:Recent phase III trial results have demonstrated the effectiveness of sipuleucel-T, a therapeutic cancer vaccine, in the treatment of metastatic prostate cancer. Yet, despite the survival benefit of sipuleucel-T, questions remain about how immunologic agents can be used in the treatment of metastatic prostate cancer. The primary issue confounding researchers and practitioners about the benefits of sipuleucel-T is the lack of effect on time to progression. It may be helpful to note that recent phase II data from a different therapeutic prostate cancer vaccine (Prostvac), as well as phase III data from an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking agent in metastatic melanoma, also show improved survival without short-term changes in disease progression. Furthermore, mathematical tumor growth models provide some insight into the fact that immunologic therapies do allow for continued tumor growth, but at a slower rate, thus prolonging survival. This understanding can help to clarify the role of the newly approved sipuleucel-T in the treatment of metastatic prostate cancer. It is also possible that appropriate sequencing of therapies could further improve the clinical course for such patients. Additional clinical trials will further our understanding of the role of therapeutic cancer vaccines and add new agents to the armamentarium of therapy for patients with prostate cancer.
journal_name
Clin Genitourin Cancerjournal_title
Clinical genitourinary cancerauthors
Madan RA,Gulley JLdoi
10.3816/CGC.2010.n.002subject
Has Abstractpub_date
2010-12-01 00:00:00pages
10-6issue
1eissn
1558-7673issn
1938-0682pii
S1558-7673(11)70002-7journal_volume
8pub_type
杂志文章,评审abstract：BACKGROUND:We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) > 18 months. PATIENTS AND METHODS:A retrospective analysis of data from 5714 patients with mRCC t...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2017.06.005
更新日期：2017-06-20 00:00:00
abstract：BACKGROUND:Smoking and obesity are known risk factors for renal cell carcinoma (RCC). We determined the influence of smoking, body mass index (BMI), and symptoms on the survival of patients with RCC. PATIENTS AND METHODS:In this retrospective study, the relative overall survival (OS) up to 25 years was calculated amon...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2013.04.017
更新日期：2013-12-01 00:00:00
abstract：PURPOSE:To determine the therapeutic value of lymph node dissection (LND) during cytoreductive nephrectomy (CN) and assess predictors of cancer-specific survival (CSS) in metastatic renal-cell carcinoma. PATIENTS AND METHODS:We identified 293 consecutive patients treated with CN at 4 academic institutions from March 2...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clgc.2017.10.004
更新日期：2018-04-01 00:00:00
abstract：OBJECTIVE:The relationship between endogenous creatinine clearance (eCrCl) and renal function values obtained using mathematical formulas has not yet been fully elucidated, especially in patients with upper tract urothelial carcinoma that are treated with radical nephroureterectomy followed by cisplatin-based chemother...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2016.04.018
更新日期：2016-10-01 00:00:00
abstract：BACKGROUND:Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multiinstitutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial c...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,多中心研究
doi：10.3816/CGC.2008.n.005
更新日期：2008-03-01 00:00:00
abstract：BACKGROUND:The programmed death-1 (PD-1) pathway negatively regulates T-cell activation and has an important role in regulating antitumor host immunity. Monoclonal antibodies directed against PD-1 or the PD-1 ligand (PD-L1) have shown activity in several tumor types with preliminary data suggesting a relationship betwe...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2015.12.002
更新日期：2016-04-01 00:00:00
abstract：BACKGROUND:Hyperglycemia and hypercholesterolemia are class effects of mammalian target of rapamycin inhibitors. The purpose of this study was to characterize safety and efficacy of patients with metastatic renal cell carcinoma (mRCC) treated with everolimus in RECORD-1 (REnal Cell cancer treatment with Oral RAD001 giv...
journal_title：Clinical genitourinary cancer
pub_type： 临床试验,杂志文章
doi：10.1016/j.clgc.2016.04.011
更新日期：2016-10-01 00:00:00
abstract：BACKGROUND:The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guérin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS:We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic c...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clgc.2019.10.021
更新日期：2020-02-01 00:00:00
abstract：BACKGROUND:Venous thromboembolism (VTE) is common in cancer patients, but there is limited data on patients with urothelial tract tumors (UTT). We previously identified several associative factors for increased VTE rates in patients with metastatic UTT. In this study, we assessed the frequency, associative factors, and...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2017.08.001
更新日期：2017-08-24 00:00:00
abstract：PURPOSE:To evaluate stage at presentation and cancer-specific mortality (CSM) in upper urinary tract tumors according to histologic subtype. METHODS:Within the Surveillance, Epidemiology, and End Results registry (SEER, 2004-2016), we identified patients with upper urinary tract tumors with pure variant histology (UTV...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2020.11.004
更新日期：2020-12-02 00:00:00
abstract：:Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was con...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,多中心研究
doi：10.3816/CGC.2008.n.023
更新日期：2008-09-01 00:00:00
abstract：BACKGROUND:The purpose of this study was to analyze contemporary trends for diagnosis and treatment of upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS:We identified all cases of UTUC in the National Cancer Database (NCDB) between 2004 and 2013. Data comprising tumor, patient, and facility factors were ex...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2018.01.015
更新日期：2018-08-01 00:00:00
abstract：BACKGROUND:Nonurothelial carcinoma (UC) malignancies have traditionally been considered to have a more aggressive clinical course, and little is known about their response to neoadjuvant therapy. We examined the effect of neoadjuvant chemotherapy (NAC) on a large population of patients with bladder cancer (BCa) with di...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2020.01.007
更新日期：2020-10-01 00:00:00
abstract：INTRODUCTION:We compared retrograde extraperitoneal open radical cystoprostatectomy (REORC) and robot-assisted radical cystoprostatectomy with intracorporeal diversion (iRARC) and have reported the early perioperative outcomes. PATIENTS AND METHODS:REORC and iRARC were each performed at a different tertiary high-volum...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2019.12.006
更新日期：2020-06-01 00:00:00
abstract：PURPOSE:Anemia is a common morbidity of advanced prostate cancer, and prostate cancer treatment and has been associated with a worse overall survival and reduced quality of life in patients with prostate cancer. We sought to determine if infrequent dosing of darbepoetin alfa is safe and effective in treating anemia in ...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.3816/CGC.2007.n.012
更新日期：2007-06-01 00:00:00
abstract：BACKGROUND:Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostatic carcinoma. PATIENTS AND METHODS:Scatter factor/HGF levels in pretreatment plasma samples from 171 men with metastatic hormone-refractory prostate canc...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.3816/CGC.2006.n.006
更新日期：2006-03-01 00:00:00
abstract：INTRODUCTION:The aims of the present study were to compare the clinicopathologic characteristics between type 1 and type 2 papillary renal cell carcinoma (pRCC) and to evaluate the effect of the subclassification of pRCC on the oncologic outcomes after surgery. MATERIALS AND METHODS:The records of 274 patients with pR...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2016.07.020
更新日期：2017-04-01 00:00:00
abstract：:Active surveillance (AS) has been claimed to avoid overtreatment of prostate cancer (PCa). It remains unclear which patients may benefit from AS. One way to clarify this is to improve the definition of insignificant PCa. PSA and Gleason score--the basic instruments used to select patients for AS--suffer from systemati...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clgc.2015.06.001
更新日期：2015-12-01 00:00:00
abstract：OBJECTIVE:Second-line systemic therapy for advanced urothelial carcinoma (UC) has substantial unmet needs, and current agents show dismal activity. Second-line trials of metastatic UC have used response rate (RR) and median progression-free survival (PFS) as primary endpoints, which may not reflect durable benefits. A ...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,meta分析
doi：10.1016/j.clgc.2013.09.002
更新日期：2014-04-01 00:00:00
abstract：:Oncocytic neoplasms are rare tumors arising in the adrenal glands and usually considered as nonfunctional and benign. We report 4 cases of adrenal oncocytic neoplasm. The paucity of literature describing this entity increases the chance for misdiagnosis. Confirmatory diagnosis is by tissue sampling with adrenalectomy ...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clgc.2018.10.011
更新日期：2019-02-01 00:00:00
abstract：INTRODUCTION:Tumor regression grades (TRGs) quantify the pathologic response to neoadjuvant chemotherapy (NAC). The aim of the study was to investigate the prognostic value of TRGs in combination with the TNM classification in an independent cohort of patients with muscle-invasive bladder cancer (MIBC) treated with NAC...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2019.09.003
更新日期：2019-12-01 00:00:00
abstract：:We present a case of a 73-year-old female with metastatic renal cell carcinoma, clear cell histologic subtype, who developed pruritic rash after 2 weeks of 25 mg weekly infusions of temsirolimus. Rash was located on bilateral antecubital areas and posterior knees. Skin biopsy showed spongiotic dermatitis with eosinoph...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.3816/CGC.2009.n.019
更新日期：2009-08-01 00:00:00
abstract：INTRODUCTION:The purpose of this study was to identify factors that are associated with quality of life (QoL) in relapse-free patients after radical prostatectomy or high-dose radiotherapy with or without hormone treatment. PATIENTS AND METHODS:A cross-sectional postal survey among members of the Norwegian Prostate Ca...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2015.07.004
更新日期：2015-12-01 00:00:00
abstract：BACKGROUND:Radical prostatectomy (RP) can cure men with unfavorable intermediate- or high-risk prostate cancer (PC). However, some will experience short prostate-specific antigen (PSA) doubling time (PSADT) failure that requires additional treatment with increased toxicity. The present study investigated whether the gr...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2015.02.012
更新日期：2015-08-01 00:00:00
abstract：BACKGROUND:Tamoxifen (TAM) has been shown to be active against the bicalutamide-induced breast events (BEs) gynecomastia, and breast pain in patients with prostate cancer (PC). Optimal doses and schedules are not yet established. Debate still exists about whether prophylaxis with TAM is more effective than treatment of...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.clgc.2012.03.002
更新日期：2012-09-01 00:00:00
abstract：INTRODUCTION:Clinical T1 (cT1) bladder cancer is associated with high rates of recurrence, upstaging, and progression. Guidelines recommend that these patients be treated with adjuvant intravesical Bacillus Calmette-Guérin immunotherapy (BCG) or upfront radical cystectomy (RC). We analyzed the National Cancer Database ...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2019.01.007
更新日期：2019-06-01 00:00:00
abstract：BACKGROUND:We comprehensively tested contemporary incidence and mortality rates in patients with germ cell tumor of the testis (GCTT). MATERIALS AND METHODS:Within the Surveillance, Epidemiology, and End Results database (2004-2015), statistical analyses included estimated annual percentage changes, multivariable logi...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2019.06.003
更新日期：2019-10-01 00:00:00
abstract：BACKGROUND:The complete remission (CR) rate with salvage systemic therapy for urothelial carcinoma (UC) is unclear, and its value as an intermediate end point and association with survival are unknown. MATERIALS AND METHODS:Data from phase II trials of salvage chemotherapy and/or biologic agents were pooled. Data rega...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2014.09.004
更新日期：2015-04-01 00:00:00
abstract：BACKGROUND:The purpose of this study was to evaluate morbidity, functional, and oncological outcomes after NSS in renal tumors > 7 cm. MATERIALS AND METHODS:We retrospectively analyzed data from 168 patients with tumors > 7 cm who were treated using NSS between 1998 and 2012. RESULTS:Imperative and elective indicatio...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2013.09.004
更新日期：2014-02-01 00:00:00
abstract：BACKGROUND:Few reports have been published regarding the outcomes of patients who develop an undescended testicular malignancy (UTM). Our objective was to analyze the sociodemographic and survival outcomes of patients with UTM and those of with descended testicular malignancy (DTM). PATIENTS AND METHODS:All 17 registr...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2015.08.004
更新日期：2016-06-01 00:00:00
